679 studies on GLP-1R mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This exploratory analysis suggests liraglutide could offer a multi-faceted therapeutic approach for individuals grappling with the complex and often debilitating combination of obesity, OSA, and COPD. By effectively p…
This comprehensive meta-analysis provides compelling and robust evidence that GLP-1 Receptor Agonists offer substantial cardiovascular and renal protection for patients with Type 2 Diabetes, critically, irrespective o…
This review underscores the critical role of adjunct therapies in optimizing metabolic health beyond insulin in Type 1 Diabetes. The findings suggest that these medications could significantly improve patient outcomes…
This umbrella review significantly expands our understanding of the pleiotropic effects of GLP-1 RAs, suggesting their therapeutic potential extends far beyond their current indications. These findings provide strong …
This research highlights a critical aspect of GLP-1 physiology: its anorectic effects are not uniform but are significantly influenced by dietary macronutrient composition. This finding could have profound implication…
This research reveals a novel mechanism by which lorcaserin contributes to appetite suppression and, more importantly, identifies a powerful synergistic interaction with GLP-1 receptor agonists. This finding suggests …
This study offers crucial insights into the sociocultural dimensions of semaglutide use, extending beyond its pharmacological effects. Understanding the social stigma and public perceptions associated with medication-…
This research highlights a crucial, often overlooked, aesthetic side effect of rapid weight loss induced by GLP-1 RAs, which can significantly impact patient satisfaction and body image. Understanding this phenomenon …
This real-world study reinforces the significant cardiovascular protective effects of GLP-1 Receptor Agonists and SGLT-2 Inhibitors in a diverse primary care population with Type 2 Diabetes. The findings provide cruci…
This review is critical for advancing the understanding and treatment of MASH, a disease with significant unmet medical needs. It provides a roadmap for developing more effective, patient-specific therapies, moving be…
This large-scale, real-world data provides crucial insights into the safety profile of GLP-1 receptor agonists when exposure occurs around conception. The reassurance regarding major congenital malformations is partic…
These pivotal Phase 3 trials definitively demonstrate that oral semaglutide 14 mg, at the tested dose and duration, is not an effective treatment for slowing cognitive decline in early symptomatic Alzheimer's disease.…
This research highlights the critical importance of considering sex as a biological variable in metabolic research and clinical practice. The observed protection in females against semaglutide-induced muscle loss coul…
The analysis revealed that a significant portion of media reports, approximately 45%, contained inaccuracies or presented information without adequate scientific context regarding the link between Semaglutide and NAIO…
This newly developed ECLIA offers a highly sensitive, specific, and robust platform for measuring semaglutide levels in human serum, significantly advancing analytical capabilities. Such a precise method is invaluable…
This real-world evidence strongly supports the effectiveness and safety of oral semaglutide in a diverse Asian population, mirroring results from controlled clinical trials. The convenience of an oral formulation can …
This study provides compelling evidence that oral semaglutide not only reduces major adverse cardiovascular events (as demonstrated in the primary SOUL trial) but also profoundly improves a wide array of individual ca…
This study provides compelling evidence that GLP-1 receptor agonists offer significant cardioprotective benefits beyond their established roles in glycemic control and weight management. The robust reduction in heart …
These findings provide critical, real-world insights into the sexual safety profiles of widely used antidiabetic medications, which are often missed in controlled clinical trials. This information is vital for healthc…
This systematic review underscores the urgent need for more comprehensive human data to guide clinical practice. Given the rising prevalence of obesity and type 2 diabetes in women of reproductive age, understanding t…
This study provides crucial evidence supporting the safety and continued efficacy of Semaglutide in a highly vulnerable patient population. For patients with type 2 diabetes and end-stage renal disease (ESRD) on dialy…
This study provides compelling evidence that semaglutide 1.7 mg is a highly effective and generally well-tolerated treatment option for adolescent obesity, a condition with limited pharmacological interventions. Given…
This study highlights a critical emerging trend in plastic surgery, demonstrating how advancements in pharmacotherapy for weight loss directly influence the demand for body contouring procedures. Understanding this sh…
This comprehensive meta-analysis provides robust evidence supporting the cardioprotective effects and favorable safety profile of GLP-1 Receptor Agonists in elderly patients with Type 2 Diabetes. Given the high burden…
This study provides crucial real-world evidence supporting the efficacy and safety of GLP-1 Receptor Agonists for managing Type 2 Diabetes in older adults, a population often underrepresented in initial clinical trial…
This comprehensive review underscores the critical role GLP-1 Receptor Agonists can play in managing Chronic Kidney Disease, moving beyond their traditional use in diabetes and obesity. The consistent evidence of sign…
This comprehensive review underscores that Semaglutide represents a significant therapeutic advancement, extending its benefits far beyond glucose control. Its dual cardioprotective and nephroprotective actions positi…
This research underscores the chronic nature of obesity and highlights that GLP-1 receptor agonists function as effective long-term management tools rather than curative treatments. The rapid weight regain and metabol…
This research highlights the significant potential of GLP-1 receptor agonists as a novel pharmacological approach for treating Alcohol Use Disorder. The substantial reduction in alcohol intake and relapse-like behavio…
The findings from such a study are profoundly significant, as they suggest semaglutide could be more than just a weight-loss drug, offering a direct therapeutic benefit for obstructive sleep apnea. This represents a n…
This research provides novel insights into the neuroprotective mechanisms of Semaglutide, demonstrating its ability to combat obesity-linked neurodegeneration by modulating microglia activation and AD-like pathology t…
This study provides crucial real-world data on the prevalence of hair shedding among GLP-1 RA users, definitively identifying rapid weight loss as a key contributing factor. Understanding this common side effect can h…
The development of these incretin-based medications marks a paradigm shift in obesity treatment, offering pharmacological options with efficacy levels previously only achievable through bariatric surgery. This advance…
This study provides compelling evidence that Tirzepatide could serve as a valuable adjunct therapy for overweight or obese individuals with Type 1 Diabetes, offering benefits beyond traditional insulin management. The…
Understanding the real-world adverse event profile of Tirzepatide and Semaglutide when used adjunctively in Type 1 Diabetes is critically important for both clinicians and patients. This information can help manage ex…
This study provides crucial evidence that optimizing the use of highly effective glucose-lowering agents can lead to substantial long-term cost savings and significantly improved patient quality of life. The findings …
This study provides crucial real-world evidence supporting the use of GLP-1 RAs in solid-organ transplant recipients, a population often excluded from pivotal trials due to complex medical profiles. The superior effic…
This robust systematic review and meta-analysis provides compelling evidence that GLP-1 receptor agonists are highly effective in achieving MASH resolution and improving liver fibrosis, addressing a major unmet medica…
These findings provide crucial evidence for healthcare policy decisions and formulary inclusions, offering a global perspective on the economic value of modern diabetes treatments. Understanding the long-term economic…
This study highlights a significant and rapid shift in GLP-1 agonist utilization patterns, extending well beyond their primary indication for type 2 diabetes into the non-diabetic population. The substantial increase …
This study provides crucial evidence that tirzepatide, a dual GIP/GLP-1 receptor agonist, offers superior cardiovascular protection compared to the established GLP-1 receptor agonist dulaglutide in patients with type …
This research provides invaluable, patient-centered insights that are crucial for optimizing the development, prescription, and long-term success of obesity pharmacotherapies. Understanding these deeply personal prefe…
This study highlights the critical challenge of maintaining weight loss after discontinuing potent anti-obesity medications like Semaglutide and Tirzepatide in a real-world clinical setting. It underscores the need fo…